My Portfolio
+
LINK YOUR PORTFOLIO

Iovance Biotherapeutics Inc IOVA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:59 PM EDT
3.90quote price arrow up+0.11 (+2.83%)
Volume
712,078
Close
3.79quote price arrow down-0.31 (-7.56%)
Volume
8,892,161
52 week range
1.66 - 5.63
Loading...
  • Open4.10
  • Day High4.12
  • Day Low3.77
  • Prev Close4.10
  • 52 Week High5.63
  • 52 Week High Date03/09/26
  • 52 Week Low1.66
  • 52 Week Low Date06/27/25

Latest On Iovance Biotherapeutics Inc

 

Key Stats

  • Market Cap1.692B
  • Shares Out446.50M
  • 10 Day Average Volume13.24M
  • Dividend-
  • Dividend Yield-
  • Beta0.70

Latest On Iovance Biotherapeutics Inc

 

KEY STATS

  • Open4.10
  • Day High4.12
  • Day Low3.77
  • Prev Close4.10
  • 52 Week High5.63
  • 52 Week High Date03/09/26
  • 52 Week Low1.66
  • 52 Week Low Date06/27/25
  • Market Cap1.692B
  • Shares Out446.50M
  • 10 Day Average Volume13.24M
  • Dividend-
  • Dividend Yield-
  • Beta0.70

RATIOS/PROFITABILITY

  • EPS (TTM)-0.95
  • P/E (TTM)-3.99
  • Fwd P/E (NTM)-8.31
  • EBITDA (TTM)-321.461M
  • ROE (TTM)-47.51%
  • Revenue (TTM)285.608M
  • Gross Margin (TTM)36.71%
  • Net Margin (TTM)-123.90%
  • Debt To Equity (MRQ)0.14%

EVENTS

  • Earnings Date08/05/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing...
Iain Dukes Ph.D.
Independent Chairman of the Board
Frederick Vogt J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Igor Bilinsky Ph.D.
Chief Operating Officer
Corleen Roche
Chief Financial Officer
Address
825 INDUSTRIAL ROAD, 4TH FLOOR
San Carlos, CA
94070
United States